Loading…
SPRC
SciSparc Ltd.
NASDAQ· Healthcare· Biotechnology· CUSIP M82618139
$6.58-0.60%Price as of Aug 29, 18:48 UTC · updated once a day, after the close
Key metrics
- Market cap
- $3.82M
- P/E
- 0.1x
- Forward P/E
- —
- P/B
- 0.6x
- Dividend yield
- —
- Payout
- —
- EPS
- $97.04
- ROE
- -178.39%
- Profit margin
- 0.00%
- Revenue growth
- -34.50%
- Beta
- 2.45
- 52-week high
- $80.10
- 52-week low
- $2.98
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.20▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $12.24 | $68.04 | $922.32 | $3,714.98 | |
| P/E | — | — | 0.3x | 0.4x | — |
| P/S | 3.4x | 5.2x | 3.0x | 1.2x | 3.8x |
| P/B | 0.6x | 1.1x | 0.5x | 0.5x | 0.8x |
| EPS | — | $203.89 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| VIVSVivoSim Labs, INC. | $0.29 | — | 0.2x | — | -343.10% | $3.82M |
| ISPCiSpecimen Inc. | $1.54 | — | 0.1x | — | -968.47% | $3.88M |
| GOVXGeoVax Labs, Inc. | $0.72 | — | 3.0x | — | -891.59% | $3.76M |
| RDHLRedHill Biopharma Ltd. | $0.66 |
About the company
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
- 3
- Tel Aviv-Yafo, Israel
Company description provided by Yahoo Finance.